Late-Stage Setback in Rare Disease: Ultragenyx shares plunged nearly 45% after its Phase III apazunersen trial in Angelman syndrome missed primary and secondary endpoints, with the company signaling program review and expense reductions. Drug Pricing Pressure: Pakistan’s pharma industry warned that proposed changes to the drug pricing mechanism could disrupt supplies and affordability, arguing the current 2018 framework was built through broad consultation and upheld by the Supreme Court. FDA Moves on Vaccines: FDA cleared Pfizer-BioNTech’s updated 2026-27 COMIRNATY XFG COVID-19 vaccine for adults 65+ and high-risk people ages 5-64, with shipping set to begin immediately. Oncology + AI in Practice: New reporting highlights how AI is being used in oncology workflows like tumor boards, while clinicians stress transparency and keeping physicians in charge. Clinical Research Watch: Can-Fite BioPharma said blinded overall survival in its LIVERATION trial for namodenoson in advanced HCC looks longer than expected, prompting an earlier interim analysis. Regulatory Scrutiny in Stem Cell Market: FDA issued a warning letter to an Arizona cord-product company over sterility validation and claims that regulators say require approval. Public Health + Recovery: SAMHSA kicked off National Recovery Month with a focus on peer support, recovery-friendly workplaces, and community-based resources.